Calico Life Sciences is focused on understanding the biology of aging by investigating the mechanisms that control lifespan, particularly through the inactivation of eLF2 alpha in the unfolded protein response pathway. The company aims to develop interventions that prevent and treat age-related diseases, enabling individuals to lead longer and healthier lives.
Funding
Funding not disclosed
Founders
Product
Problem
Aging is a complex biological process that increases the risk of various diseases and reduces overall healthspan. Understanding the underlying mechanisms that control lifespan is critical for developing interventions that can prevent or treat age-related diseases. Current research faces challenges in identifying and targeting the key pathways involved in aging and age-related decline.
Solution
Calico Life Sciences is a research and development company focused on deciphering the biology of aging. By employing advanced technologies and computational approaches, Calico aims to identify the fundamental mechanisms that govern lifespan and age-related diseases. The company's strategy involves a systems biology approach, integrating diverse data sets to understand how genetic, environmental, and lifestyle factors influence the aging process. Calico seeks to translate these insights into novel interventions that can extend healthy lifespan and mitigate the impact of age-related conditions. Through collaborations with academic institutions and other biopharmaceutical companies, Calico is building a pipeline of early- and clinical-stage compounds targeting diseases commonly linked with aging.
Target Audience
Calico's primary focus is on developing interventions that benefit individuals at risk of or affected by age-related diseases, as well as the broader scientific community interested in understanding the biology of aging.
Features
- Systems biology approach integrating diverse datasets to understand aging mechanisms
- Focus on identifying key pathways and targets involved in age-related diseases
- Utilization of advanced technologies and computational capabilities for data analysis and modeling
- Development of interventions to extend healthy lifespan and prevent age-related decline
- Collaborative partnerships with academic institutions and biopharmaceutical companies
- Pipeline of early- and clinical-stage compounds targeting diseases commonly linked with aging